Tay Therapeutics – a spin out from the University of Dundee

Founded in 2020 from the Drug Discovery Unit at the University of Dundee, Tay Therapeutics has emerged as a leader in biotech innovation, discovering and advancing three candidate drugs in just four years.  With a highly effective team and a cost-efficient semi-virtual model, Tay accelerates the development of novel therapies for genetic diseases and obesity. 

In 2021, Tay licensed a Bromodomain and Extra-Terminal Domain (BET) inhibitor to VYNE Therapeutics as a potential immune-inflammatory treatment. Now called Repibresib, it has advanced to Phase 2b clinical trials in vitiligo.  

In 2023, Tay licensed a second drug to Vyne Therapeutics. VYN202 is a selective oral BET inhibitor, which has completed Phase 1a trials and will enter psoriasis trials in 2025. These deals represent over $80 million in upfront and milestone payments, plus up to 10% royalties. 

Building on its BET success, Tay is now advancing a new class of small-molecule gene therapies to restore functional proteins by bypassing mutations, targeting diseases at their root. In parallel, it is developing a muscle-sparing anti-obesity therapy, reinforcing its focus on high-impact, first-in-class treatments. 

Tay is backed by investors including o2h Ventures, Meltwind, Wren Capital, Scottish Enterprise, and the University of Dundee. With a track record of fast, cost-effective, high-value drug discovery, Tay is redefining biotech efficiency—delivering transformative medicines with speed and impact.